Maxim Group Reiterates “Buy” Rating for PainReform (NASDAQ:PRFX)

Maxim Group reissued their buy rating on shares of PainReform (NASDAQ:PRFX) in a research note published on Wednesday morning, Benzinga reports. Maxim Group currently has a $2.00 price objective on the stock.

PainReform Trading Down 3.7 %

Shares of PRFX opened at $0.48 on Wednesday. The stock has a 50-day simple moving average of $0.71 and a 200-day simple moving average of $1.59. PainReform has a 1 year low of $0.45 and a 1 year high of $26.41.

PainReform (NASDAQ:PRFX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($2.72) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On PainReform

An institutional investor recently bought a new position in PainReform stock. Armistice Capital LLC bought a new position in shares of PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned about 10.90% of PainReform as of its most recent SEC filing. Institutional investors own 37.28% of the company’s stock.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.